EnVVeno Medical Corporation (NASDAQ:NVNO) | WebDisclosure

Basculer en Français

10184	Companies
209583	Keywords
139725	Articles
111119	Press releases

Headlines Articles Press releases EnVVeno Medical Corporation

Home
Companies
EnVVeno Medical Corporation

PRESS RELEASE

published on 04/16/2024 at 15:00, 1 year 11 months ago

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation

VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium
BRIEF

published on 04/09/2024 at 14:50, 2 years ago

EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization

EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
BRIEF

published on 04/09/2024 at 14:50, 2 years ago

EnVVeno Medical nomme Andrew Cormack au poste de directeur commercial pour diriger la commercialisation de VenoValve®

EnVVeno Medical VenoValve® Insuffisance Veineuse Chronique (IVC) Étude Pivot Américaine SAVVE Stratégie De Commercialisation
PRESS RELEASE

published on 04/09/2024 at 14:45, 2 years ago

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024

FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
BRIEF

published on 03/15/2024 at 14:05, 2 years ago

EnVVeno Medical to Showcase Its Innovations in an Upcoming Virtual Investor Event

EnVVeno Medical Medical Innovation Virtual Investor Event Venous Disease Treatment Corporate Overview
BRIEF

published on 03/15/2024 at 14:05, 2 years ago

EnVVeno Medical présentera ses innovations lors d'un prochain événement virtuel pour les investisseurs

Innovation Médicale EnVVeno Medical Événement Virtuel Pour Les Investisseurs Traitement Des Maladies Veineuses Vue D'ensemble De L'entreprise
PRESS RELEASE

published on 03/15/2024 at 14:00, 2 years ago

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
enVVeno Medical to present at Virtual Investor Lunch Break on March 21, 2024, with CEO Robert Berman discussing the company's outlook and the enVVeno Opportunity

EnVVeno Medical Venous Disease Treatment Virtual Investor Lunch Break Robert Berman Bioprosthetic Solutions
BRIEF

published on 03/06/2024 at 14:45, 2 years 1 month ago

EnVVeno Medical Corporation Announces Positive Results from VenoValve Pivotal Trial

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Clinical Improvement
BRIEF

published on 03/06/2024 at 14:45, 2 years 1 month ago

EnVVeno Medical Corporation annonce les résultats positifs de l'essai pivot VenoValve

EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Approbation De La FDA Amélioration Clinique
PRESS RELEASE

published on 03/06/2024 at 14:40, 2 years 1 month ago

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
enVVeno Medical presents positive topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum Annual Meeting, showing significant clinical improvement in CVI patients

EnVVeno Medical VenoValve Clinical Improvement SAVVE Trial CVI Patients

Accesswire

Published on 04/10/2026 at 02:15, 5 hours 2 minutes ago

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Published on 04/10/2026 at 01:05, 6 hours 12 minutes ago

Pathfinder Ventures Inc. Announces Tranche Closing of Financing and Extension of Private Placement
Published on 04/10/2026 at 00:00, 7 hours 17 minutes ago

Redwood AI Announces Upgraded Cloud-Based Reactosphere Platform with Enhanced Security and Expanded Core Capabilities
Published on 04/09/2026 at 23:15, 8 hours 2 minutes ago

Digi Power X Enters into Amended and Restated Sales Agreement
Published on 04/09/2026 at 23:05, 8 hours 12 minutes ago

Caldwell Reports Second Quarter Results

View all ACCESSWIRE

EQS Group

Published on 04/10/2026 at 07:00, 17 minutes ago

Lindt & Sprüngli completes buyback of own shares and participation certificates ahead of schedule and launches new buyback program in May
Published on 04/10/2026 at 06:00, 1 hour 17 minutes ago

Sales for the first quarter 2026
Published on 04/09/2026 at 22:00, 9 hours 17 minutes ago

Invitation - First Quarter 2026 Trading Update Conference Call
Published on 04/09/2026 at 21:01, 10 hours 16 minutes ago

GEVELOT S.A.: PRESS RELEASE CLOSING OF 2025 ACCOUNTS
Published on 04/09/2026 at 21:01, 10 hours 16 minutes ago

GEVELOT S.A.: COMMUNIQUE ARRETE DES COMPTES 2025

Les Echos

Published on 04/09/2026 at 21:49, 9 hours 27 minutes ago

Résultats 2025 consolidés de NSC Groupe
Published on 04/09/2026 at 20:00, 11 hours 17 minutes ago

SMTPC - Communiqué sur le Chiffre d'affaires du 1er trimestre 2026
Published on 04/09/2026 at 18:35, 12 hours 42 minutes ago

Mise à disposition des documents préparatoires à l'Assemblée Générale Mixte du 30 avril 2026
Published on 04/09/2026 at 18:35, 12 hours 42 minutes ago

Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 18:00, 13 hours 17 minutes ago

i2S : Chiffre d'Affaires T1 2026

View all LES ECHOS COMFI WIRE